



FINECURE PHARMACEUTICALS LIMITED, AHMEDABAD, INDIA

AQUACEF

CEFUROXIME AXETIL ORAL SUSPENSION BP

1.3.1 Summary of Product Characteristics (SmPC)

1.1 Name of medicinal product

Cefuroxime Axetil Oral Suspension BP (125 mg/5 ml)

1.2 Strength

Cefuroxime Axetil BP equivalent to Cefuroxime..... 125 mg

1.3 Pharmaceutical Dosage form

Powder for Oral (For oral administration)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 5 ml of reconstituted suspension contains:

Cefuroxime Axetil BP equivalent to Cefuroxime..... 125 mg

Excipients..... q.s

Colour: Ponceau 4R

3. PHARMACEUTICAL FORM

Powder for Oral

Pink coloured crystalline powder which becomes red coloured suspension on addition of water.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Cefuroxime Axetil is indicated for the treatment of the infections listed below in adults and children from the age of 3 months.

- Acute streptococcal tonsillitis and pharyngitis.
- Acute bacterial sinusitis



FINECURE PHARMACEUTICALS LIMITED, AHMEDABAD, INDIA

AQUACEF

CEFUROXIME AXETIL ORAL SUSPENSION BP

- Acute otitis media.
- Acute exacerbations of chronic bronchitis
- Cystitis.
- Pyelonephritis.
- Uncomplicated skin and soft tissue infections.
- Treatment of early Lyme disease.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

4.2 Posology and method of administration

The usual course of therapy is seven days (may range from five to ten days).

Table 1. Adults and children (≥ 40 kg)

Indication	Dosage
Acute tonsillitis and pharyngitis, acute bacterial sinusitis	250 mg twice daily
Acute otitis media	500 mg twice daily
Acute exacerbations of chronic bronchitis	500 mg twice daily
Cystitis	250 mg twice daily
Pyelonephritis	250 mg twice daily
Uncomplicated skin and soft tissue infections	250 mg twice daily
Lyme disease	500 mg twice daily for 14 days (range of 10 to 21 days)

Table 2. Children (< 40 kg)

Indication	Dosage
Acute tonsillitis and pharyngitis, acute bacterial sinusitis	10 mg/kg twice daily to a maximum of 125 mg twice daily



FINECURE PHARMACEUTICALS LIMITED, AHMEDABAD, INDIA

AQUACEF

CEFUROXIME AXETIL ORAL SUSPENSION BP

Children aged two years or older with otitis media or, where appropriate, with more severe infections	15 mg/kg twice daily to a maximum of 250 mg twice daily
Cystitis	15 mg/kg twice daily to a maximum of 250 mg twice daily
Pyelonephritis	15 mg/kg twice daily to a maximum of 250 mg twice daily for 10 to 14 days
Uncomplicated skin and soft tissue infections	15 mg/kg twice daily to a maximum of 250 mg twice daily
Lyme disease	15 mg/kg twice daily to a maximum of 250 mg twice daily for 14 days (10 to 21 days)

There is no experience of using Cefuroxime Axetil Oral Suspension BP in children under the age of 3 months.

Cefuroxime axetil tablets and cefuroxime axetil granules for oral suspension are not bioequivalent and are not substitutable on a milligram-per-milligram basis (see section 5.2).

In infants (from the age of 3 months) and children with a body mass of less than 40kg, it may be preferable to adjust dosage according to weight or age. The dose in infants and children 3 months to 18 years is 10 mg/kg twice daily for most infections, to a maximum of 250 mg daily. In otitis media or more severe infections the recommended dose is 15 mg/kg twice daily to a maximum of 500 mg daily.

The following two tables, divided by age group, serve as a guideline for simplified administration, e.g. measuring spoon (5 mL), for the 125 mg/5 mL or the 250 mg/5 mL multi-dose suspension if provided, and 125 mg or 250 mg single dose sachets.

Table 3. 10 mg/kg dosage for most infections.



FINECURE PHARMACEUTICALS LIMITED, AHMEDABAD, INDIA

AQUACEF

CEFUROXIME AXETIL ORAL SUSPENSION BP

Age	Dose (mg) twice daily	Volume per dose (mL)		No. of sachets per dose	
		125 mg	250 mg	125 mg	250 mg
3 to 6 months	40 to 60	2.5	-	-	-
6 months to 2 years	60 to 120	2.5 to 5	-	-	-
2 to 18 years	125	5	2.5	1	-

Table 4. 15 mg/kg dosage for otitis media and more serious infections

Age	Dose (mg) twice daily	Volume per dose (mL)		No. of sachets per dose	
		125 mg	250 mg	125 mg	250 mg
3 to 6 months	60 to 90	2.5	-	-	-
6 months to 2 years	90 to 180	5 to 7.5	2.5	1 (125 mg)	-
2 to 18 years	180 to 250	7.5 to 10	2.5 to 5	2 (250 mg)	1 (250 mg)

Renal impairment

The safety and efficacy of cefuroxime axetil in patients with renal failure have not been established. Cefuroxime is primarily excreted by the kidneys. In patients with markedly impaired renal function it is recommended that the dosage of cefuroxime should be reduced to compensate for its slower excretion. Cefuroxime is effectively removed by dialysis.

Table 5. Recommended doses for Cefuroxime Axetil Oral Suspension BP in renal impairment

Creatinine clearance	T _{1/2} (hrs.)	Recommended dosage
≥30 mL/min/1.73 m ²	1.4–2.4	no dose adjustment necessary (standard dose of 125 mg to 500 mg given twice daily)



FINECURE PHARMACEUTICALS LIMITED, AHMEDABAD, INDIA

AQUACEF

CEFUROXIME AXETIL ORAL SUSPENSION BP

10-29 mL/min/1.73 m ²	4.6	standard individual dose given every 24 hours
----------------------------------	-----	---

<10 mL/min/1.73 m ²	16.8	standard individual dose given every 48 hours
Patients on hemodialysis	2-4	a further standard individual dose should be given at the end of each dialysis

Hepatic impairment

There are no data available for patients with hepatic impairment. Since cefuroxime is primarily eliminated by the kidney, the presence of hepatic dysfunction is expected to have no effect on the pharmacokinetics of cefuroxime.

Method of administration

Oral use

For optimal absorption cefuroxime axetil suspension should be taken with food.

4.3 Contraindications

Hypersensitivity to cefuroxime or to any of the excipients.

Patients with known hypersensitivity to cephalosporin antibiotics.

History of severe hypersensitivity (e.g. anaphylactic reaction) to any other type of beta lactam antibacterial agent (penicillin, monobactams and carbapenems).

4.4 Special warnings and special precautions for use

Hypersensitivity reactions

Special care is indicated in patients who have experienced an allergic reaction to penicillins or other beta-lactam antibiotics because there is a risk of cross-sensitivity. As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported. In case of severe hypersensitivity reactions, treatment with cefuroxime must be discontinued immediately and adequate emergency measures must



FINECURE PHARMACEUTICALS LIMITED, AHMEDABAD, INDIA

AQUACEF

CEFUROXIME AXETIL ORAL SUSPENSION BP

be initiated.

Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to cefuroxime, to other cephalosporins or to any other type of beta-lactam agent. Caution should be used if cefuroxime is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents.

Jarisch-Herxheimer reaction

The Jarisch-Herxheimer reaction has been seen following cefuroxime axetil treatment of Lyme disease. It results directly from the bactericidal activity of cefuroxime axetil on the causative bacteria of Lyme disease, the spirochaete *Borrelia burgdorferi*. Patients should be reassured that this is a common and usually self-limiting consequence of antibiotic treatment of Lyme disease.

Overgrowth of non-susceptible microorganisms

As with other antibiotics, use of cefuroxime axetil may result in the overgrowth of *Candida*. Prolonged use may also result in the overgrowth of other non-susceptible microorganisms (e.g. enterococci and *Clostridium difficile*), which may require interruption of treatment.

Antibacterial agent-associated pseudomembranous colitis have been reported with nearly all antibacterial agents, including cefuroxime and may range in severity from mild to life threatening. This diagnosis should be considered in patients with diarrhoea during or subsequent to the administration of cefuroxime. Discontinuation of therapy with cefuroxime and the administration of specific treatment for *Clostridium difficile* should be considered. Medicinal products that inhibit peristalsis should not be given.

Interference with diagnostic tests

The development of a positive Coomb's Test associated with the use of cefuroxime may interfere with cross matching of blood.

As a false negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase methods are used to determine blood/plasma glucose levels in patients receiving cefuroxime axetil.



FINECURE PHARMACEUTICALS LIMITED, AHMEDABAD, INDIA

AQUACEF

CEFUROXIME AXETIL ORAL SUSPENSION BP

Important information about excipients

The sucrose content of cefuroxime axetil suspension and granules should be taken into account when treating diabetic patients and appropriate advice provided.

Contains 3 g of sucrose per 5 mL dose

Contains 3 g of sucrose per unit dose

Cefuroxime axetil suspension contains aspartame, which is a source of phenylalanine and so should be used with caution in patients with phenylketonuria.

4.5 Interaction with other medicinal products and other forms of Interaction

Drugs which reduce gastric acidity may result in a lower bioavailability of cefuroxime axetil compared with that of the fasting state and tend to cancel the effect of enhanced absorption after food.

Cefuroxime axetil may affect the gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral contraceptives.

Cefuroxime is excreted by glomerular filtration and tubular secretion. Concomitant use of probenecid is not recommended. Concurrent administration of probenecid significantly increases the peak concentration, area under the serum concentration time curve and elimination half-life of cefuroxime.

Concomitant use with oral anticoagulants may give rise to increased INR.

4.6 Pregnancy and lactation

Pregnancy

There are limited data from the use of cefuroxime in pregnant women. Studies in animals have shown no harmful effects on pregnancy, embryonal or foetal development, parturition or postnatal development. Cefuroxime Axetil Oral Suspension BP should be prescribed to pregnant women only if the benefit outweighs the risk.

Breastfeeding

Cefuroxime is excreted in human milk in small quantities. Adverse effects at therapeutic doses are not expected, although a risk of diarrhoea and fungus infection of the mucous membranes cannot be excluded. Breastfeeding might have to be discontinued due to



FINECURE PHARMACEUTICALS LIMITED, AHMEDABAD, INDIA

AQUACEF

CEFUROXIME AXETIL ORAL SUSPENSION BP

these effects. The possibility of sensitisation should be taken into account. Cefuroxime should only be used during breastfeeding after benefit/risk assessment by the physician in charge.

Fertility

There are no data on the effects of cefuroxime axetil on fertility in humans. Reproductive studies in animals have shown no effects on fertility.

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. However, as this medicine may cause dizziness, patients should be warned to be cautious when driving or operating machinery.

4.8 Undesirable effects

The most common adverse reactions are Candida overgrowth, eosinophilia, headache, dizziness, gastrointestinal disturbances and transient rise in liver enzymes.

The frequency categories assigned to the adverse reactions below are estimates, as for most reactions suitable data (for example from placebo-controlled studies) for calculating incidence were not available. In addition the incidence of adverse reactions associated with cefuroxime axetil may vary according to the indication.

Data from large clinical studies were used to determine the frequency of very common to rare undesirable effects. The frequencies assigned to all other undesirable effects (i.e. those occurring at $<1/10,000$) were mainly determined using post-marketing data and refer to a reporting rate rather than true frequency. Placebo-controlled trial data were not available. Where incidences have been calculated from clinical trial data, these were based on drug-related (investigator assessed) data. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

Treatment related adverse reactions, all grades, are listed below by Med DRA body system organ class, frequency and grade of severity. The following convention has been utilized for the classification of frequency: very common $\geq 1/10$; common $\geq 1/100$ to $< 1/10$, uncommon $\geq 1/1,000$ to $< 1/100$; rare $\geq 1/10,000$ to $< 1/1,000$; very rare $< 1/10,000$



FINECURE PHARMACEUTICALS LIMITED, AHMEDABAD, INDIA

AQUACEF

CEFUROXIME AXETIL ORAL SUSPENSION BP

and not known (cannot be estimated from the available data).

System organ class	Common	Uncommon	Not known
Infections and infestations	Candida overgrowth		Clostridium difficile overgrowth
Blood and lymphatic system disorders	eosinophilia	positive Coomb's test, thrombocytopenia,	haemolytic anaemia

		leukopenia (sometimes profound)	
Immune system disorders			drug fever, serum sickness, anaphylaxis, Jarisch-Herxheimer reaction
Nervous system disorders	headache, dizziness		
Gastrointestinal disorders	diarrhoea, nausea, abdominal pain	vomiting	pseudomembranous colitis (see section 4.4)
Hepatobiliary disorders	transient increases of hepatic enzyme levels		jaundice (predominantly cholestatic), hepatitis
Skin and subcutaneous tissue disorders		skin rashes	urticaria, pruritus, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (exanthematic necrolysis) (see Immune system disorders), angioneurotic oedema

Description of selected adverse reactions

Cephalosporins as a class tend to be absorbed onto the surface of red cells membranes and react with antibodies directed against the drug to produce a positive Coombs' test (which can interfere with cross-matching of blood) and very rarely haemolytic anaemia.

Transient rises in serum liver enzymes have been observed which are usually reversible.



FINECURE PHARMACEUTICALS LIMITED, AHMEDABAD, INDIA

AQUACEF

CEFUROXIME AXETIL ORAL SUSPENSION BP

4.9 Overdose

Overdose can lead to neurological sequelae including encephalopathy, convulsions and coma. Symptoms of overdose can occur if the dose is not reduced appropriately in patients with renal impairment.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: antibacterials for systemic use, second-generation cephalosporins, ATC code: J01DC02

Mechanism of action

Cefuroxime axetil undergoes hydrolysis by esterase enzymes to the active antibiotic, cefuroxime.

Cefuroxime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.

Mechanism of resistance

Bacterial resistance to cefuroxime may be due to one or more of the following mechanisms:

- hydrolysis by beta-lactamases; including (but not limited to) by extended-spectrum beta-lactamases (ESBLs), and AmpC enzymes that may be induced or stably derepressed in certain aerobic Gram-negative bacteria species;
- reduced affinity of penicillin-binding proteins for cefuroxime;
- outer membrane impermeability, which restricts access of cefuroxime to penicillin binding proteins in Gram-negative bacteria;
- bacterial efflux pumps.

Organisms that have acquired resistance to other injectable cephalosporins are expected to be resistant to cefuroxime.

Depending on the mechanism of resistance, organisms with acquired resistance to penicillins may demonstrate reduced susceptibility or resistance to cefuroxime.



FINECURE PHARMACEUTICALS LIMITED, AHMEDABAD, INDIA

AQUACEF

CEFUROXIME AXETIL ORAL SUSPENSION BP

5.2 Pharmacokinetic properties

Absorption

After oral administration cefuroxime axetil is absorbed from the gastrointestinal tract and rapidly hydrolysed in the intestinal mucosa and blood to release cefuroxime into the circulation. Optimum absorption occurs when it is administered shortly after a meal.

Following administration of cefuroxime axetil tablets peak serum levels (2.9 µg/mL for a 125 mg dose, 4.4 µg/mL for a 250 mg dose, 7.7 µg/mL for a 500 mg dose and 13.6 µg/mL for a 1000 mg dose) occur approximately 2.4 hours after dosing when taken with food. The rate of absorption of cefuroxime from the suspension is reduced compared with the tablets, leading to later, lower peak serum levels and reduced systemic bioavailability (4 to 17% less). Cefuroxime axetil oral suspension was not bioequivalent to cefuroxime axetil tablets when tested in healthy adults and therefore is not substitutable on a milligram-per-milligram basis. The pharmacokinetics of cefuroxime is linear over the oral dosage range of 125 to 1000 mg. No accumulation of cefuroxime occurred following repeat oral doses of 250 to 500 mg.

Distribution

Protein binding has been stated as 33 to 50% depending on the methodology used. Following a single dose of cefuroxime axetil 500 mg tablet to 12 healthy volunteers, the apparent volume of distribution was 50 L (CV%=28%). Concentrations of cefuroxime in excess of the minimum inhibitory levels for common pathogens can be achieved in the tonsilla, sinus tissues, bronchial mucosa, bone, pleural fluid, joint fluid, synovial fluid, interstitial fluid, bile, sputum and aqueous humor. Cefuroxime passes the blood-brain barrier when the meninges are inflamed.

Biotransformation

Cefuroxime is not metabolised.

Elimination

The serum half-life is between 1 and 1.5 hours. Cefuroxime is excreted by glomerular



FINECURE PHARMACEUTICALS LIMITED, AHMEDABAD, INDIA

AQUACEF

CEFUROXIME AXETIL ORAL SUSPENSION BP

filtration and tubular secretion. The renal clearance is in the region of 125 to 148 mL/min/1.73 m².

Special patient populations

Gender

No differences in the pharmacokinetics of cefuroxime were observed between males and females.

Elderly

No special precaution is necessary in the elderly patients with normal renal function at dosages up to the normal maximum of 1 g per day. Elderly patients are more likely to have decreased renal function; therefore, the dose should be adjusted in accordance with the renal function in the elderly.

Paediatrics

In older infants (aged >3 months) and in children, the pharmacokinetics of cefuroxime are similar to that observed in adults.

There is no clinical trial data available on the use of cefuroxime axetil in children under the age of 3 months.

Renal impairment

The safety and efficacy of cefuroxime axetil in patients with renal failure have not been established.

Cefuroxime is primarily excreted by the kidneys. Therefore, as with all such antibiotics, in patients with markedly impaired renal function (i.e. C₁cr <30 mL/minute) it is recommended that the dosage of cefuroxime should be reduced to compensate for its slower excretion. Cefuroxime is effectively removed by dialysis.



FINECURE PHARMACEUTICALS LIMITED, AHMEDABAD, INDIA

AQUACEF

CEFUROXIME AXETIL ORAL SUSPENSION BP

Hepatic impairment

There are no data available for patients with hepatic impairment. Since cefuroxime is primarily eliminated by the kidney, the presence of hepatic dysfunction is expected to have no effect on the pharmacokinetics of cefuroxime.

PK/PD relationship

For cephalosporins, the most important pharmacokinetic-pharmacodynamic index correlating with in vivo efficacy has been shown to be the percentage of the dosing interval (%T) that the unbound concentration remains above the minimum inhibitory concentration (MIC) of cefuroxime for individual target species (i.e. %T>MIC).

5.3 Preclinical safety data

Preclinical effects were observed in dosages far above the maximal human dosage which are therefore hardly relevant for the clinical use of Cefuroxime Axetil.

6. PHARMACEUTICAL PARTICULARS

6.1 List of Excipients

Color Ponceau 4R Supra, Sucrose, Sodium Benzoate, Colloidal Silicon Dioxide, Sodium Citrate, and Microcrystalline Cellulose powder, Aspartame, Essence Dry Orange and Essence Dry Peppermint.

6.2 Incompatibilities

Not Applicable.

6.3 Shelf life

24 months

6.4 Special precautions for storage

Powder for Oral Suspension: Please Do not store above 30°C. Keep the container



FINECURE PHARMACEUTICALS LIMITED, AHMEDABAD, INDIA

AQUACEF

CEFUROXIME AXETIL ORAL SUSPENSION BP

tightly closed. Store in the original container.

Oral Suspension: Store at 2°C - 8°C. Do not freeze. Keep the container tightly closed.

6.5 Nature and contents of container

100 ml ring white HDPE bottle with 25 mm white cap with induction seal and measuring cup in a carton along with pack insert.

6.6 Special precautions for disposal

No special requirements. Any unused product or waste material should be disposed of in accordance with local requirements.

7. Manufacturer

M/s. Finecure Pharmaceuticals Limited,

Shimla Pistaar, Malsa Road,

Udham Singh Nagar.

Rudrapur, Uttrakhand, India.

Phone: + (91)-(5944)-281048

Fax No.: + (91)-(5944)-280889

E-mail: niraj@finecurepharma.in

8. Date of revision of the text

Not Applicable